CD25 deficiency causes an immune dysregulation, polyendocrinopathy, enteropathy, X-linked–like syndrome, and defective IL-10 expression from CD4 lymphocytes

Amy A. Caudy, PhD,^a Sreelatha T. Reddy, PhD,^d Talal Chatila, MD,^b John P. Atkinson, MD,^c and James W. Verbsky, MD, PhD^d Princeton, NJ, Los Angeles, Calif, St Louis, Mo,

and Milwaukee, Wis

Background: Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) results in systemic autoimmunity from birth and can be caused by mutations in the transcription factor forkhead box P3 (FOXP3).

Objective: To determine if Foxp3 is required for the generation of IL-10–expressing T regulatory cells.

Methods: CD4 lymphocytes were isolated from patients with IPEX-like syndromes and activated with antibodies to CD3 and CD46 to generate IL-10–expressing T regulatory cells. Results: We describe a patient with clinical manifestations of IPEX that had a normal Foxp3 gene, but who had CD25 deficiency due to autosomal recessive mutations in this gene. This patient exhibited defective IL-10 expression from CD4 lymphocytes, whereas a Foxp3-deficient patient expressed normal levels of IL-10.

Conclusion: These data show that CD25 deficiency results in an IPEX-like syndrome and suggests that although Foxp3 is not required for normal IL-10 expression by human CD4 lymphocytes, CD25 expression is important.

Clinical implications: Any patient with features of IPEX but with a normal Foxp3 gene should be screened for mutations in the IL-2 receptor subunit CD25. (J Allergy Clin Immunol 2007;119:482-7.)

Key words: IPEX, IL-10, IL-2, CD25, Foxp3

ions used
Cytomegalovirus
Forkhead box P3
IL-2 receptor
immune dysregulation, polyendocrinopathy,
enteropathy, X-linked
T-regulatory

T-regulatory (T_R) cells are critical to immune regulation and are organized into CD25⁺ forkhead box P3 (Foxp3)⁺ natural T_R cells and cytokine-expressing adaptive T_R cells.^{1,2} Patients lacking Foxp3 have the immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome, characterized by diabetes mellitus, thyroiditis, eczema, severe allergies, and enteropathy.^{3,4} Importantly, approximately 1/3 of patients with the IPEX syndrome do not have mutations in FOXP3.⁵ Adaptive T_R cells secrete immunosuppressive cytokines (IL-10 and TGF- β), and studies suggest a role for these cells in immune regulation.^{6,7} The physiologic relationship between these cell types is unknown.

CD4 lymphocytes stimulated with antibodies to the Tcell receptor subunit CD3 and the complement regulatory protein CD46 express high levels of IL-10, which is able to inhibit naive T-cell proliferation, a characteristic of adaptive T_R cells.⁸ IL-2 is required for IL-10 production in this model. Previous studies have shown that activation of human CD4 lymphocytes results in the de novo expression of Foxp3.9 To test whether the expression of IL-10 requires Foxp3, we studied IL-10 production by CD4 lymphocytes from 2 patients with syndromes consistent with IPEX: one patient with a known mutation in FOXP3, and a second patient with a normal FOXP3 coding sequence. These studies revealed that the Foxp3-deficient patient with IPEX expressed normal levels of IL-10, whereas the second patient exhibited defective IL-10 production because of a deficiency of CD25. Importantly, staining of CD4 lymphocytes from the CD25-deficient patient with antibodies to Foxp3 showed normal numbers of circulating Foxp3⁺ cells. This report shows that an IPEX-like syndrome can be caused by a defect in CD25.

From ^athe Lewis-Sigler Institute for Integrative Genomics, Princeton University; ^bthe Division of Immunology, Allergy and Rheumatology, Department of Pediatrics, David Geffen School of Medicine at the University of California at Los Angeles; ^cthe Division of Rheumatology, Department of Medicine, Washington University School of Medicine, St Louis; and ^dthe Division of Rheumatology, Department of Pediatrics, Medical College of Wisconsin.

Supported by National Institutes of Health grant R01-AI37618 (J.P.A.), R01-AI065617 (T.C.), the Washington University Rheumatology Postdoctoral Training Grant (A.A.C.), the Abbott Scholar Award in Rheumatology Research (J.W.V.), and the Children's Research Institute (S.T.R., J.W.V.).

Disclosure of potential conflict of interest: J. W. Verbsky has received an Abbott Scholar Award. The rest of the authors have declared that they have no conflict of interest.

Received for publication September 1, 2006; revised October 4, 2006; accepted for publication October 5, 2006.

Available online December 30, 2006.

Reprint requests: James Verbsky, MD, PhD, Assistant Professor of Pediatrics, Medical College of Wisconsin, Children's Corporate Center, Pediatric Rheumatology, Suite C465, 9000 W Wisconsin Ave, PO Box 1997, Milwaukee, WI 53201-1997. E-mail: jverbsky@mcw.edu. 0091-6749/\$32.00

^{© 2007} American Academy of Allergy, Asthma & Immunology doi:10.1016/j.jaci.2006.10.007

These studies raise important questions regarding the role of IL-2 in the function of $Foxp3^+$ cells, as well as the relationship of IL-2 and IL-10 in regulating immune responses.

METHODS

CD4 lymphocyte isolation and activation

PBMCs were obtained using Ficoll-Paque (Amersham, Piscataway, NJ) and CD4 lymphocytes isolated with magnetic beads (Miltenyi Biotec, Auburn, Calif) under an Institutional Review Board–approved human studies protocol (Washington University, St Louis, Mo). Cells were activated with plate-bound antibodies to CD3 (OKT3, American Type Tissue Collection) and CD46 (Tra2-10) with human IL-2 or human IL-15 (eBioscience, San Diego, Calif), or with 10 ng/mL phorbol 12-myristate 13-acetate and 1 µmol/L ionomycin (Sigma, St Louis, Mo).

Flow cytometry/ELISA

Lymphocytes stimulated as described for 3 days were stained with antibodies to CD69–fluorescein isothiocyanate (FN50), CD25allophycocyanin (M-A251), CD4-phycoerythrin (RPA-T4, BD Biosciences, San Jose, Calif), and Foxp3-APC (PCH101, eBioscience) and analyzed on a FACSCalibur flow cytometer (Becton-Dickinson, Franklin Lakes, NJ). Tissue culture supernatants were analyzed for IL-10 production by using an IL-10 ELISA (eBioscience).

cDNA analysis and cloning

RNA was isolated from human lymphocytes with a RNAeasy column (Qiagen, Valencia, Calif), and cDNA was generated by using the IM-PROM II reverse transcriptase system and oligo-dT (Promega, Madison, Wis). The full-length CD25 cDNA was amplified with Red-Taq DNA polymerase (Sigma) by using the following primers: 5'-ACATGGATTCATACCTGC-3' and 5'-GATTGTTCTTCTACT CTT-3'. The 0.8-kb fragment was cloned into pCMV-Tag1 (Stratagene, La Jolla, Calif) and individual colonies sequenced. In some studies, the PCR products were concentrated and digested with BbsI (New England Biolabs, Ipswich, Mass) and separated on a 2.5% agarose gel.

Case presentation

The patient is an 8-year-old white boy born to unrelated parents with an uneventful pregnancy and delivery. At 6 weeks of age, he developed severe diarrhea, insulin-dependent diabetes mellitus, and eventual respiratory failure. Urine and blood cultures were positive for cytomegalovirus (CMV). Lung biopsy showed dense mononuclear cell lung infiltrates containing plasma cells and immunohistochemical staining positive for CMV. Intestinal biopsy showed chronic inflammation with CMV inclusion bodies. Laboratory evaluation showed a serum IgG of 850 mg/dL, IgA of 125 mg/dL, IgM of 168 mg/dL, and a lymphocyte CD3 count of 3251 cells/µL with 33% CD4 cells and 28% CD8 cells. Antiviral therapy was initiated with clearance of the CMV, but the diarrhea persisted. Repeat endoscopy at 6 months of age showed chronic inflammation with villous atrophy consistent with autoimmune enteropathy. By 2 years of age, he had developed diffuse eczema, systemic lymphadenopathy, hepatosplenomegaly, enlarged tonsils, and symptoms of sleep apnea requiring tonsillectomy and adenoidectomy. Lymph node biopsies showed lymphoid hyperplasia with evidence of EBV. By 3 years of age, he had developed hypothyroidism and severe autoimmune hemolytic anemia. CMV was again detected in his urine. Laboratory workup showed a hemoglobin of 10.7 g/dL, platelet count of 411,000/µL, white blood cell count of 10,700 cells/µL, IgA of 297 mg/dL, IgG of 1630 mg/dL, IgM of 85 mg/dL, and IgE of 120 IU/mL. At 5 years, he developed antigranulocyte antibody–positive neutropenia and had persistent sinusitis and otitis media requiring sinus surgery, repeat myringotomy tubes, and frequent antibiotics. Over the period of the next 3 years, he developed asthma, had recurrent pneumonias, and exhibited persistent lymphadenopathy, hepatosplenomegaly, eczema, and diarrhea with protein-losing enteropathy. During the course of his illness, he was treated with numerous medications, including corticosteroids, rituximab, intravenous immunoglobulin, cyclosporin, and antibiotics. Because of his enteropathy, endocrinopathy, eczema, hemolytic anemia, hepatosplenomegaly, and lymphadenopathy, he was diagnosed with an IPEX-like syndrome, and FOXP3 gene sequencing was performed, but no coding sequence mutations were found (data not shown¹⁰).

RESULTS

CD25 expression, but not Foxp3, is required for IL-10 production

To test whether Foxp3 expression was required for IL-10 production from human CD4 lymphocytes, 2 patients with syndromes consistent with IPEX were analyzed. One patient had a known FOXP3 coding sequence mutation (FOXP3⁻),³ and the second patient had a normal Foxp3 coding sequence (Foxp3⁺, described). CD4 lymphocytes were isolated and stimulated with antibodies to CD3 and CD46, or CD3 and CD28 in the presence of IL-2. As shown in Fig 1, A, the Foxp3⁻ patient expressed levels of IL-10 comparable to controls, whereas the Foxp3⁺ patient failed to express detectable IL-10. Because this model of IL-10 production is dependent on exogenous IL-2, and because animal models deficient in the IL-2 receptor subunits have autoimmune phenomena similar to mice deficient in Foxp3, we examined the IL-2 receptor components in the Foxp3⁺ patient.^{8,11,12} Activation of CD4 lymphocytes from a control subject resulted in strong upregulation of CD25, whereas no CD25 was detected on CD4 lymphocytes from the Foxp3⁺ patient with IPEX (Fig 1, B). The early activation marker CD69, however, was induced in this patient's lymphocytes. Pharmacologic activation with phorbol 12-myristate 13-acetate and ionomycin resulted in upregulation of CD25 and CD69 from normal lymphocytes, but only CD69 was expressed in the Foxp3⁺ patient (data not shown).

Because no CD25 was expressed from the Foxp3⁺ patient, sequence analysis was performed on the CD25 gene from PCR-amplified cDNA. Sequence analysis revealed a single base pair insertion after position 692 in 1 allele of his CD25 gene that resulted in a frameshift mutation just proximal to the transmembrane domain (Fig 1, C). Transfection studies showed that this protein was not surface-expressed and did not prevent the expression of wild-type CD25 (data not shown). Sequence analysis of the patient's mother confirmed the single base pair insertion in one of her CD25 alleles (data not shown). Genomic sequencing revealed a second allele with a C to T substitution at position 301 resulting in a stop codon (Fig 1, C). Sequence analysis of the patient's father confirmed the single base pair substitution at position 301 (data not shown). Finally, PBMCs were isolated from

Download English Version:

https://daneshyari.com/en/article/3202160

Download Persian Version:

https://daneshyari.com/article/3202160

Daneshyari.com